Insider Transactions in Q2 2021 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.25%
|
$65,000
$13.76 P/Share
|
|
May 12
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
3,000
+22.6%
|
$33,000
$11.27 P/Share
|
|
May 11
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
1,500
+22.5%
|
$16,500
$11.16 P/Share
|
|
May 11
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
2,500
+40.32%
|
$25,000
$10.96 P/Share
|
|
May 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+8.27%
|
$60,000
$3.02 P/Share
|
|
May 11
2021
|
Peter Greenleaf Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,125
+17.57%
|
$51,250
$10.63 P/Share
|
|
May 11
2021
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Open market or private purchase
|
Direct |
9,900
+50.0%
|
$99,000
$10.07 P/Share
|
|
May 11
2021
|
Joseph M Miller Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$9,000
$9.74 P/Share
|
|
May 11
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+21.79%
|
$120,000
$3.02 P/Share
|